About

Ramit Lamba is associated with the UC Davis Department of Radiology, where he serves as the Program Director for the Integrated Interventional Radiology Residency. His role involves overseeing the training and education of medical students and residents in the field of radiology, with a focus on interventional radiology. As an Assistant Clinical Professor, he contributes to the academic and clinical development of radiology education at UC Davis Health, supporting opportunities for students to learn about diagnostic and interventional radiology through shadowing, research projects, and rotations.

Research topics

• Medicine
• Radiology
• Internal medicine
• Pathology
• Surgery
• Medical emergency
• Gynecology
• Obstetrics
• Oncology
• Medical physics
• Gastroenterology

Selected publications

• Update on Management of Incidental Findings Seen on Imaging Studies of the Abdomen and Pelvis

  Radiographics · 2026-03-05

  article

  Since the publication of the American College of Radiology white papers on incidental findings in the abdomen and pelvis, numerous studies have been published that either support or contradict existing guidelines or address common incidental findings for which no white paper exists.

  PublisherDOI

• Image-guided renal parenchymal biopsies– how we do it

  Abdominal Radiology · 2024-11-25 · 1 citations

  review
  PublisherDOI

• Extremity radiographs derived from low-dose ultra-high-resolution CT: a phantom study

  Skeletal Radiology · 2024-02-03 · 1 citations

  article
  PublisherDOI

• A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy

  Clinical Colorectal Cancer · 2023-02-24 · 1 citations

  articleOpen access
  PublisherOA PDFDOI

• Imaging of Hepatobiliary Cancer

  Current Problems in Cancer · 2023-04-01 · 2 citations

  reviewSenior author
  PublisherDOI

• Large variation in radiation dose for routine abdomen CT: reasons for excess and easy tips for reduction

  European Radiology · 2023-09-21 · 12 citations

  articleOpen access

  Abstract Objective To characterize the use and impact of radiation dose reduction techniques in actual practice for routine abdomen CT. Methods We retrospectively analyzed consecutive routine abdomen CT scans in adults from a large dose registry, contributed by 95 hospitals and imaging facilities. Grouping exams into deciles by, first, patient size, and second, size-adjusted dose length product (DLP), we summarized dose and technical parameters and estimated which parameters contributed most to between-protocols dose variation. Lastly, we modeled the total population dose if all protocols with mean size-adjusted DLP above 433 or 645 mGy-cm were reduced to these thresholds. Results A total of 748,846 CTs were performed using 1033 unique protocols. When sorted by patient size, patients with larger abdominal diameters had increased dose and effective mAs (milliampere seconds), even after adjusting for patient size. When sorted by size-adjusted dose, patients in the highest versus the lowest decile in size-adjusted DLP received 6.4 times the average dose (1680 vs 265 mGy-cm) even though diameter was no different (312 vs 309 mm). Effective mAs was 2.1-fold higher, unadjusted CTDI vol 2.9-fold, and phase 2.5-fold for patients in the highest versus lowest size-adjusted DLP decile. There was virtually no change in kV (kilovolt). Automatic exposure control was widely used to modulate mAs, whereas kV modulation was rare. Phase was the strongest driver of between-protocols variation. Broad adoption of optimized protocols could result in total population dose reductions of 18.6–40%. Conclusion There are large variations in radiation doses for routine abdomen CT unrelated to patient size. Modification of kV and single-phase scanning could result in substantial dose reduction. Clinical relevance Radiation dose-optimization techniques for routine abdomen CT are routinely under-utilized leading to higher doses than needed. Greater modification of technical parameters and number of phases could result in substantial reduction in radiation exposure to patients. Key Points • Based on an analysis of 748,846 routine abdomen CT scans in adults, radiation doses varied tremendously across patients of the same size and optimization techniques were routinely under-utilized. • The difference in observed dose was due to variation in technical parameters and phase count. Automatic exposure control was commonly used to modify effective mAs, whereas kV was rarely adjusted for patient size. Routine abdomen CT should be performed using a single phase, yet multi-phase was common. • kV modulation by patient size and restriction to a single phase for routine abdomen indications could result in substantial reduction in radiation doses using well-established dose optimization approaches.

  PublisherOA PDFDOI

• Utility of combined gadoxetic acid and ferumoxytol-enhanced liver MRI for preoperative detection of colorectal cancer liver metastases: a pilot study

  Acta Radiologica · 2022 · 7 citations

  • Medicine
  • Radiology
  • Internal medicine

  BACKGROUND: Colorectal cancer (CRC) is the second-leading cause of cancer-related death worldwide and resection of CRC metastases confined to the liver is the treatment of choice when feasible. Ferumoxytol is an off-label contrast agent that opacifies vasculature and may be helpful in distinguishing metastases from small hemangiomas and blood vessels on gadoxetic acid-enhanced magnetic resonance imaging (MRI). PURPOSE: To compare the diagnostic accuracy of MRI using a standard gadoxetic acid protocol and a combined gadoxetic acid/ferumoxytol protocol in patients with suspected colorectal hepatic metastases. MATERIAL AND METHODS: In this institutional review board-approved, single-institution, retrospective study, eight patients underwent gadoxetic acid-enhanced liver MRI, supplemented with additional T1-weighted ferumoxytol enhanced sequences. Two radiologists in consensus identified all metastases using all available sequences, which served as the reference standard. Two different radiologists reviewed each exam twice, once using the standard protocol and once with additional ferumoxytol sequences. The detection rate was estimated as the predicted probability of a metastasis along with the 95% confidence interval (CI) using hierarchical logistic regression models. RESULTS: A total of 49 metastases were identified. The mean diameter was 10 mm, measured in greatest axial dimension (median=7 mm; range=2-70 mm). Readers 1 and 2 had detection rates of 69.6% (95% CI = 48.2-85.0) and 53.1% (95% CI = 35.2-70.3) for gadoxetic acid alone and 98.0% (95% CI = 86.3-99.7) and 83.5% (95% CI = 59.3-94.7) for combined protocol. CONCLUSION: In this preliminary investigation, adding ferumoxytol-enhanced sequences to gadoxetic acid liver MRI protocol increased the detection rate of CRC hepatic metastases and may aid in preoperative decision making.

  PublisherDOI

• Retained Morbidly Adherent Placenta Presenting as a Myometrial Mass in Patients With Vaginal Bleeding

  Ultrasound Quarterly · 2022 · 2 citations

  • Medicine
  • Obstetrics
  • Radiology

  ABSTRACT: The differential diagnosis for a uterine mass and vaginal bleeding after abortion or delivery is broad and includes both benign and malignant causes. A rare etiology for this condition is retained morbidly adherent placenta. Few cases of retained morbidly adherent placenta presenting as a myometrial mass in the setting of vaginal bleeding have been described in the medical literature. In this case series and review of the current literature, we describe the ultrasound features of 3 retained morbidly adherent placentae, along with correlative magnetic resonance imaging findings.

  PublisherDOI

• Phase I/II trial of BMS-986205 and nivolumab as first line therapy in hepatocellular carcinoma.

  Journal of Clinical Oncology · 2022 · 2 citations

  • Medicine
  • Internal medicine
  • Oncology

  e16200 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme expressed by HCC which helps to orchestrate immune suppression within the tumor microenvironment (TME) and may contribute to primary and acquired resistance of PD-(L)1 inhibitors. BMS-986205 is a novel oral drug that potently and selectively inhibits IDO1. This Phase I/II study is evaluating the safety and tolerability of the combination of BMS-986205 and nivolumab as first-line therapy in HCC. Methods: Patients (pts) ≥18y with untreated, unresectable/metastatic HCC received BMS-986205 in combination with nivolumab. A fixed dose of Nivolumab 240mg/m 2 IV was administered on Day 1 of each 14-day cycle. BMS-986205 was an oral tablet administered daily; a total of two dose levels (50-100mg) were given to determine dose limiting toxicities (DLT) during the dose-escalation Phase I of the study. Safety was assessed using CTCAE v5.0 criteria, and efficacy was assessed by objective response rate (ORR) using RECIST v1.1 criteria. Secondary objectives included preliminary data on disease control rate (DCR), duration of response (DOR), ORR using immune RECIST criteria (iRECIST), progression free survival (PFS) and overall survival (OS). Results: Here we report the results of the dose escalation cohort. Eight pts were treated with median age 69y [60-76]; 75% male; and PS 0 (3 pts) or 1 (5 pts). Pts were White (62.5%), Asian (25%), and African American (12.5%). Six of 8 pts had underlying viral hepatitis (5 hepatitis C, 1 hepatitis B), and all pts were Child Pugh A at enrollment with median baseline alpha-fetoprotein (AFP) level 41.8 [3.8–917.2]; 4 pts received prior local therapies. A total of 91 cycles of therapy were administered; 2 pts received 27 and 43 cycles of treatment each. Six pts were evaluable for DLT; 2 pts were replaced for DLT assessment due to insufficient dose administered, unrelated to toxicity. No DLTs were observed at either the 50 or 100mg dose of BMS-986205. There were 24 treatment-related adverse events (TRAEs), 4 of which were Grade 3 events; there were no Grade 4-5 events. The most common TRAEs of all grades were AST elevation and ALT elevation in 3 pts, and diarrhea, maculopapular rash and increased alkaline phosphatase in 2 pts each. Grade 3 events were diarrhea and AST elevation (1 pt), and hyperglycemia and pancreatitis requiring treatment discontinuation (1 pt). Eight pts were evaluable for efficacy with best response of partial response in 1 pt (12.5%) and stable disease in 3 pts (37.5%), yielding a DCR of 50%. Median PFS was 8.5 weeks; median OS has not been reached. Conclusions: Combination BMS-986205 and nivolumab showed a manageable safety profile with durable benefit as 1 st line therapy in a meaningful subset of patients with unresectable/metastatic HCC. Clinical trial information: NCT03695250.

  PublisherDOI

• Incidental Pancreatic Cysts on Cross-Sectional Imaging

  Radiologic Clinics of North America · 2021-05-27 · 4 citations

  reviewSenior author
  PublisherDOI

Frequent coauthors

• Michael T. Corwin

  University of California, Davis

  36 shared

• Ghaneh Fananapazir

  University of California, Davis

  24 shared

• John P. McGahan

  University of California, Davis

  16 shared

• John M. Boone

  University of California, Davis

  14 shared

• Temel Tirkes

  Indiana University School of Medicine

  10 shared

• Eric vanSonnenberg

  University of Phoenix

  9 shared

• Thomas W. Loehfelm

  University of California, San Diego

  8 shared

• Rebecca Smith‐Bindman

  University of California, San Francisco

  7 shared

Education

• M.D.

  University of California, Davis

• Other

  University of Delhi

Awards & honors

• RSNA Honored Educator Award - 2014
• Fellow of the Society for Abdominal Radiology (2015)
• Certificate of Merit for Educational Exhibit “Simple and Eas…
• Certificate of Merit for Educational Exhibit “Point Counter…